Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

110 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunotherapy for sarcomas: new frontiers and unveiled opportunities.
Birdi HK, Jirovec A, Cortés-Kaplan S, Werier J, Nessim C, Diallo JS, Ardolino M. Birdi HK, et al. Among authors: diallo js. J Immunother Cancer. 2021 Feb;9(2):e001580. doi: 10.1136/jitc-2020-001580. J Immunother Cancer. 2021. PMID: 33526607 Free PMC article. Review.
Oncolytic Maraba Virus MG1 as a Treatment for Sarcoma.
Le Boeuf F, Selman M, Son HH, Bergeron A, Chen A, Tsang J, Butterwick D, Arulanandam R, Forbes NE, Tzelepis F, Bell JC, Werier J, Abdelbary H, Diallo JS. Le Boeuf F, et al. Among authors: diallo js. Int J Cancer. 2017 Sep 15;141(6):1257-1264. doi: 10.1002/ijc.30813. Epub 2017 Jun 21. Int J Cancer. 2017. PMID: 28568891 Free article.
The strategic combination of trastuzumab emtansine with oncolytic rhabdoviruses leads to therapeutic synergy.
Arulanandam R, Taha Z, Garcia V, Selman M, Chen A, Varette O, Jirovec A, Sutherland K, Macdonald E, Tzelepis F, Birdi H, Alluqmani N, Landry A, Bergeron A, Vanderhyden B, Diallo JS. Arulanandam R, et al. Among authors: diallo js. Commun Biol. 2020 May 22;3(1):254. doi: 10.1038/s42003-020-0972-7. Commun Biol. 2020. PMID: 32444806 Free PMC article.
Personalized oncology and BRAFK601N melanoma: model development, drug discovery, and clinical correlation.
Keller BA, Laight BJ, Varette O, Broom A, Wedge MÈ, McSweeney B, Cemeus C, Petryk J, Lo B, Burns B, Nessim C, Ong M, Chica RA, Atkins HL, Diallo JS, Ilkow CS, Bell JC. Keller BA, et al. Among authors: diallo js. J Cancer Res Clin Oncol. 2021 May;147(5):1365-1378. doi: 10.1007/s00432-021-03545-2. Epub 2021 Feb 8. J Cancer Res Clin Oncol. 2021. PMID: 33555379
Identification of FDA-approved bifonazole as a SARS-CoV-2 blocking agent following a bioreporter drug screen.
Taha Z, Arulanandam R, Maznyi G, Godbout E, Carter-Timofte ME, Kurmasheva N, Reinert LS, Chen A, Crupi MJF, Boulton S, Laroche G, Phan A, Rezaei R, Alluqmani N, Jirovec A, Acal A, Fekete EEF, Singaravelu R, Petryk J, Idorn M, Potts KG, Todesco H, John C, Mahoney DJ, Ilkow CS, Giguère P, Alain T, Côté M, Paludan SR, Olagnier D, Bell JC, Azad T, Diallo JS. Taha Z, et al. Among authors: diallo js. Mol Ther. 2022 Sep 7;30(9):2998-3016. doi: 10.1016/j.ymthe.2022.04.025. Epub 2022 May 6. Mol Ther. 2022. PMID: 35526097 Free PMC article.
Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer.
Crupi MJF, Taha Z, Janssen TJA, Petryk J, Boulton S, Alluqmani N, Jirovec A, Kassas O, Khan ST, Vallati S, Lee E, Huang BZ, Huh M, Pikor L, He X, Marius R, Austin B, Duong J, Pelin A, Neault S, Azad T, Breitbach CJ, Stojdl DF, Burgess MF, McComb S, Auer R, Diallo JS, Ilkow CS, Bell JC. Crupi MJF, et al. Among authors: diallo js. Front Immunol. 2022 Nov 3;13:1029269. doi: 10.3389/fimmu.2022.1029269. eCollection 2022. Front Immunol. 2022. PMID: 36405739 Free PMC article.
Vanadyl sulfate-enhanced oncolytic virus immunotherapy mediates the antitumor immune response by upregulating the secretion of pro-inflammatory cytokines and chemokines.
Alluqmani N, Jirovec A, Taha Z, Varette O, Chen A, Serrano D, Maznyi G, Khan S, Forbes NE, Arulanandam R, Auer RC, Diallo JS. Alluqmani N, et al. Among authors: diallo js. Front Immunol. 2022 Nov 28;13:1032356. doi: 10.3389/fimmu.2022.1032356. eCollection 2022. Front Immunol. 2022. PMID: 36532027 Free PMC article.
Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, sensitizes cancer cells to VSVΔ51 oncolytic virotherapy.
Wong B, Bergeron A, Maznyi G, Ng K, Jirovec A, Birdi HK, Serrano D, Spinelli M, Thomson M, Taha Z, Alwithenani A, Chen A, Lorimer I, Vanderhyden B, Arulanandam R, Diallo JS. Wong B, et al. Among authors: diallo js. Mol Ther. 2023 Nov 1;31(11):3176-3192. doi: 10.1016/j.ymthe.2023.09.017. Epub 2023 Sep 27. Mol Ther. 2023. PMID: 37766429
110 results